Home|Journals|Articles by Year|Audio Abstracts
 

Short Communication

J App Pharm Sci. 2022; 12(4): 179-184


Synthesis and in vitro cytotoxic activity of novel indazole analogues of curcumin against MCF-7, HeLa, WiDr, and vero cell lines

Hariyanti Hariyanti, Arry Yanuar, Kusmardi Kusmardi, Hayun Hayun.




Abstract
Cited by 1 Articles

We prepared six novel curcumin indazole analogs and confirmed their structures by Fourier transform infrared, nuclear magnetic resonance, and mass spectra. Subsequently, their cytotoxicity was tested using the Michigan Cancer Foundation (MCF-7) proliferation assay against the Michigan Cancer Foundation (MCF-7), HeLa, WiDr, and vero cell lines. This study found that the compounds we prepared were more active against WiDr than HeLa and MCF-7. The activity of 3b, 3c, 3d, and 5a against WiDr (colorectal carcinoma) cells was higher than curcumin and tamoxifen. Their selectivity index (SI) indicated that several synthesized compounds showed more selectivity (SI value > 2) than positive controls tamoxifen and doxorubicin (SI value < 2.00). Three compounds (3a, 3b, and 3c) showed high SI against WiDr cells (3.74, 5.27, and 4.39, respectively). Compound 3b produced the highest cytotoxic activity, especially against WiDr cells (IC50 = 27.20 μM) with excellent selectivity (SI = 5.27). Therefore, the compound should be further developed as an anticancer agent for colorectal carcinoma.

Key words: curcumin indazole analogs, cytotoxicity, selectivity, MCF-7, HeLa, WiDr, Vero






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.